Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript Summary
Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript Summary
Gross profit margin was 80%, slightly down from 81% in the previous year.The following is a summary of the Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript:
以下是zynex公司 (ZYXI) 2024年第三季度業績會簡報：
Financial Performance:
金融業績：
Zynex reported Q3 2024 revenue of $50 million, essentially flat compared to Q3 2023.
Net income was $2.4 million with diluted earnings per share of $0.07.
Gross profit margin was 80%, slightly down from 81% in the previous year.
Operating cash flow was robust, totaling $10 million for the first nine months of the year.
The company expects a 9% revenue increase for 2024, with projected revenues of $200 million and diluted earnings per share of $0.20.
Zynex報告2024年第三季度營業收入爲5000萬美元，與2023年第三季度基本持平。
淨利潤爲240萬美元，每股攤薄收益爲0.07美元。
毛利潤率爲80%，略低於前一年的81%。
經營性現金流強勁，截至年初九個月累計1000萬美元。
公司預計2024年營收將增長9%，預計營收爲20000萬美元，每股攤薄收益爲0.20美元。
Business Progress:
業務進展：
Zynex announced FDA clearance for TensWave, a device for transcutaneous electrical nerve stimulation.
Major milestones were achieved in patient monitoring solutions, including advancements with the NiCO pulse oximeter expected to complete FDA 510(k) submission by Q4 2024.
Significant order growth in rehab products, which now constitute 31% of total orders.
Continual optimization of sales force, including strategic replacement and addition of sales reps to enhance productivity and increase orders.
zynex宣佈TensWave獲得FDA許可，這是一種用於經皮電神經刺激的設備。
在患者監測解決方案方面取得重大里程碑，包括NiCO脈搏血氧計的進展，預計將於2024年第四季度完成FDA 510(k)提交。
康復產品訂購量顯著增長，現在佔總訂單的31%。
持續優化銷售團隊，包括戰略性更換和增加銷售代表，以增強生產力並提高訂單量。
Opportunities:
機會：
Expected growth in non-opioid pain management and expansion in hospital monitoring solutions present significant opportunities for Zynex.
Newly approved products like TensWave and advancements in patient monitoring technology such as the NiCO pulse oximeter are anticipated to drive market share and diversify revenue sources.
預計非阿片類疼痛管理和醫院監測解決方案的增長爲zynex帶來重大機遇。
像TensWave這樣的新獲批產品以及NiCO脈搏血氧計等患者監測技術的進展預計將推動市場份額增長和多樣化營收來源。
Risks:
風險：
Slowing device revenue and the need for pruned and optimized sales force may affect short-term profitability and market penetration.
設備營業收入放緩以及修剪和優化銷售隊伍的需求可能會影響短期盈利能力和市場滲透率。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
